Imagine a tiny, smart straw—only a couple of centimeters long—that sits inside a blood vessel. It acts like a 24/7 health monitor, checking blood pressure and chemical markers without the patient feeling a thing. This data is sent straight to a smartphone, allowing doctors to spot heart failure before it becomes an emergency.
Patients with heart failure often suffer from high re-hospitalization and mortality rates because doctors lack continuous, real-time data on hemodynamic behavior and biomarkers.
A miniaturized multi-sensing implantable device (1-2 cm long) capable of measuring blood pressure, vessel deformation, oximetry, haematocrit, glucose, and cardiac troponins.
If you are a medical device developer dealing with the lack of continuous in-vivo data—this project developed a multi-sensing platform measuring 1-2 cm long and 2-4 mm in diameter that provides real-time hemodynamic and biochemical data.
If you are a digital health company dealing with fragmented patient data—this project developed a system that transfers measured data wirelessly via NFC or smartphones to enable early intervention against heart failures.
If you are a biotech firm dealing with the difficulty of integrating multiple sensors into one small footprint—this project developed a platform using 3D printing and two-photon lithography to combine pressure, oximetry, and biomarker sensors.
Based on available project data, there is no specific information regarding the unit cost or commercial pricing of the device.
The project utilizes advanced fabrication techniques like 3D printing and two-photon lithography, but based on available project data, industrial scale-up metrics are not yet provided.
Based on available project data, the IP details and licensing terms are not specified in the project summary.
The system is powered by and connected to an external data collection system using standardized wireless technology such as NFC or smartphones.
The project period runs from 2023-09-01 to 2027-08-31, suggesting the technology is currently in the development phase.
The consortium is heavily research-oriented, consisting of 5 partners from 4 countries (DE, ES, IE, IT). It is composed of 3 research organizations and 2 universities, with 0% industry participation. This indicates the project is currently focused on high-risk, high-gain scientific discovery rather than immediate commercialization.
Contact Fondazione Istituto Italiano di Tecnologia
Contact us to find licensing opportunities for this bioelectronic sensing platform.
